Antibe Analyst Call – Positive Phase 2B Dose-Ranging, Efficacy Results
June 4, 2020 | Conference Call
Antibe hosted a conference call to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. Management provided a brief summary of the results which was followed by a Q&A session for analysts. Please click on the “Read” link below to listen to an audio replay of the call.